Page 180 - Read Online

Page 6 of 8 Zheng et al. Hepatoma Res 2018;4:17 I http://dx.doi.org/10.20517/2394-5079.2018.08

patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:64-70.
7. Su LJ, Wang LH, Hsieh WC, Wu HC, Teng CF, Tsai HW, Huang W. The emerging role of hepatitis B virus pre-S2 deletion mutant
proteins in HBV tumorigenesis. J Biomed Sci 2014;21:98.
8. Su LJ, Hsieh WC, Tsai HW, Wu HC. Chemoprevention and novel therapy for hepatocellular carcinoma associated with chronic hepatitis
B virus infection. Hepatobiliary Surg Nutr 2013;2:37-9.
9. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M. Guidotti LG.
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad
Sci U S A 2012;109:E2165-72.
10. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
11. Liu S, Koh SS, Lee CG. Hepatitis B virus X protein and hepatocarcinogenesis. Int J Mol Sci 2016;17:179.
12. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010;52:594-604.
13. Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol 2016;22:1943-52.
14. Su LJ, Wang HC, Wu HC, Huang WY. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic
hepatitis B virus infection. J Gastroenterol Hepatol 2008;23:1169-74.
15. Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC. The influence of hepatitis B viral load and pre-S
deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy.
PLoS One 2013;8:e66457.
16. Yen CJ, Ai YL, Tsai HW, Chan SH, Yen CS, Cheng KH, Lee YP, Kao CW, Wang YC, Chen YL, Lin CH, Liu T, Tsai HP, Wang JR, Su
LJ, Huang W. Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic
resection. Hepatology 2018; doi: 10.1002/hep.29790.
17. Qu LS, Chen YY, Zhang HF, Liu JX, Lu CH. Pre-S deletions of hepatitis B virus predict recurrence of hepatocellular carcinoma after
curative resection. Medicine 2017;96:e8311.
18. Wang HC, Chang WT, Chang WW, Wu HC, Huang W, Lei HY, Lai MD, Fausto N, Su LJ. Hepatitis B virus pre-S2 mutant upregulates
cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 2005;41:761-70.
19. Wang HC, Huang W, Lai MD, Su LJ. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer
Sci 2006;97:683-8.
20. Sinn DH, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Pre-s mutation is a significant risk factor for
hepatocellular carcinoma development: a long-term retrospective cohort study. Dig Dis Sci 2013;58:751-8.
21. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985;317:489-95.
22. Luan F, Liu H, Gao L, Liu J, Sun Z, Ju Y, Hou N, Guo C, Liang X, Zhang L, Sun W, Ma C. Hepatitis B virus protein preS2 potentially
promotes HCC development via its transcriptional activation of hTERT. Gut 2009;58:1528-37.
23. Hildt E, Hofschneider PH. The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer
Res 1998;154:315-29.
24. Schluter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. Integrated hepatitis B virus X and 3’ truncated preS/S sequences
derived from human hepatomas encode functionally active transactivators. Oncogene 1994;9:3335-44.
25. Milich DR, McNamara MK, McLachlan A, Thornton GB, Chisari FV. Distinct H-2-linked regulation of T-cell responses to the pre-S
and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl
Acad Sci U S A 1985;82:8168-72.
26. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, Chisari FV. Enhanced immunogenicity of the pre-S region of
hepatitis B surface antigen. Science 1985;228:1195-9.
27. Berthelot P, Neurath R, Courouce AM, Brechot C, Degos F, Tron F, Girard M. Hepatitis B vaccines with pre-S gene product. Lancet
1986;1:1150.
28. Neurath AR, Adamowicz P, Kent SB, Riottot MM, Strick N, Parker K, Offensperger W, Petit MA, Wahl S, Budkowska A.
Characterization of monoclonal antibodies specific for the pre-S2 region of the hepatitis B virus envelope protein. Mol Immunol
1986;23:991-7.
29. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-44.
30. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Anti Ther 2010;15:3-14.
31. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J
Hepatol 2014;61:408-17.
32. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or
chronic infections despite immunoprophylaxis. Hepatology 1997;26:786-91.
33. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced
antigenic change affect immunization? Bull World Health Organ 2010;88:66-73.
34. Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M. Naturally occurring escape
mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J
Virol 1994;68:2671-6.
35. Raimondo G, Costantino L, Caccamo G, Pollicino T, Squadrito G, Cacciola I, Brancatelli S. Non-sequencing molecular approaches to
identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol 2004;40:515-9.
36. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011;32:1122-32.
37. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007;127:164-76.